SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences:
- A corporate presentation at the Canaccord Genuity 43rd Annual Growth Conference in Boston, at 9:30 a.m. ET (6:30 a.m. PT) on Thursday, August 10, 2023.
- A fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference at 10:30 a.m. ET (7:30 a.m. PT) on Thursday, August 17, 2023.
A live audio webcast of the presentations will be available in the Investors section of the Harpoon Therapeutics website at www.harpoontx.com with an archived replay available following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com and follow us on Twitter and LinkedIn.
Source: Harpoon Therapeutics Inc.